Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Meghan Sri Karuturi"'
Autor:
Khandan Keyomarsi, Debu Tripathy, Kelly K. Hunt, David J. Tweardy, Aysegul Sahin, Stephanie S. Watowich, Meghan Sri Karuturi, Nuhad K. Ibrahim, Akshara S. Raghavendra, T. Kris Eckols, Xian Chen, Jason P.W. Carey, Min Yi, Jing Wang, Xiayu Rao, Bin Liu, Min Jin Ha, Mehrnoosh Kohansal, Tuyen Bui, Merih Guray Durak, Smruthi Vijayaraghavan, Nicole M. Kettner
Supplementary Data from Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1719d34a1d0e6d9e8f4e1ddbf5167f1f
https://doi.org/10.1158/1078-0432.22475867.v1
https://doi.org/10.1158/1078-0432.22475867.v1
Autor:
Khandan Keyomarsi, Debu Tripathy, Kelly K. Hunt, David J. Tweardy, Aysegul Sahin, Stephanie S. Watowich, Meghan Sri Karuturi, Nuhad K. Ibrahim, Akshara S. Raghavendra, T. Kris Eckols, Xian Chen, Jason P.W. Carey, Min Yi, Jing Wang, Xiayu Rao, Bin Liu, Min Jin Ha, Mehrnoosh Kohansal, Tuyen Bui, Merih Guray Durak, Smruthi Vijayaraghavan, Nicole M. Kettner
Purpose:Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are currently used in combination with endocrine therapy to treat advanced hormone receptor–positive, HER2-negative breast cancer. Although this treatment doubles time to progression compared
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866981ce359d67f9e3d05d0e9295d988
https://doi.org/10.1158/1078-0432.c.6529199
https://doi.org/10.1158/1078-0432.c.6529199
Autor:
Marjory Charlot, Stephanie B. Wheeler, Trevor A. Jolly, Ethan Basch, Elizabeth Claire Dees, Meghan Sri Karuturi, Lisa A. Carey, Emily Damone, KE Reeder-Hayes, Raquel E. Reinbolt, Gretchen Kimmick, Joellen C. Speca, William A. Wood, Allison Mary Deal, Bryce B. Reeve, Shlomit S. Shachar, Kirsten A. Nyrop, Hyman B. Muss
Publikováno v:
Breast Cancer Research and Treatment. 191:409-422
It is not known whether chemotherapy-related symptom experiences differ between Black and White women with early breast cancer (Stage I–III) receiving current chemotherapy regimens and, in turn, influences dose delay, dose reduction, early treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ed50895627628d681d377815a38bfcb9
https://doi.org/10.1007/s10549-021-06439-6
https://doi.org/10.1007/s10549-021-06439-6
Autor:
Reshma Mahtani, Janice M. Walshe, Eustratios Bananis, Meghan Sri Karuturi, D. Lu, Sindy T. Kim, Patrick Schnell, Anil A. Joy, Karen A. Gelmon, Patrick Neven, Lee S. Schwartzberg
Publikováno v:
Breast, Vol 59, Iss, Pp 321-326 (2021)
The Breast : Official Journal of the European Society of Mastology
The Breast : Official Journal of the European Society of Mastology
Objective In the PALOMA-2 trial, palbociclib in combination with letrozole prolonged progression-free survival (PFS) and exhibited an acceptable safety profile in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0104cae2c0a2c79565e498e192266c5c
http://www.sciencedirect.com/science/article/pii/S0960977621004252
http://www.sciencedirect.com/science/article/pii/S0960977621004252
Autor:
Maureen G. Conlan, Wael A. Harb, Robert Wesolowski, Meghan Sri Karuturi, Donald A. Richards, Peter Kabos, Rebecca G. Bagley, Paul Conkling, Cynthia Osborne, Aditya Bardia, Amy Weise, Sharon Wilks, Virginia G. Kaklamani, Yamei Wang
Publikováno v:
Journal of Clinical Oncology. 39:1360-1370
PURPOSE This phase I study (RAD1901-005; NCT02338349) evaluated elacestrant, an investigational oral selective estrogen receptor degrader (SERD), in heavily pretreated women with estrogen receptor–positive, human epidermal growth factor receptor 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11c91dfdb659722ad29b115c559dd2bb
https://doi.org/10.1200/jco.20.02272
https://doi.org/10.1200/jco.20.02272
Autor:
Gildy Babiera, Nina Tamirisa, Sharon H. Giordano, Meghan Sri Karuturi, Heather Lin, Yu Shen, Simona F. Shaitelman, Isabelle Bedrosian
Publikováno v:
Cancer
BACKGROUND: Data are lacking as to the benefit of adjuvant endocrine therapy(ET) in older patients with multiple comorbidities. We sought to determine the impact of ET on survival in older patients with multiple comorbidities and estrogen receptor po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16c5f4cad008c2d1293f96b1c7d9fc36
https://doi.org/10.1002/cncr.33489
https://doi.org/10.1002/cncr.33489
Autor:
Joanne L. Blum, Meghan Sri Karuturi, Timothy J. Pluard, Erin Jepsen, Yao Wang, Thomas Stanton, Jay Anderson, Joseph C. Cappelleri, Adnan Garrett, Debu Tripathy, Faith Beery, Kenneth Manning
Publikováno v:
Cancer Research. 81:PS7-19
Background: POLARIS is an ongoing, prospective, real world, noninterventional study in patients (pts) with HR+/HER2– ABC receiving PAL. This interim report describes real-world PAL use in preMeno pts. Methods: POLARIS has a targeted enrollment of 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7012143a71fd9acce842d29dd7c35f80
https://doi.org/10.1158/1538-7445.sabcs20-ps7-19
https://doi.org/10.1158/1538-7445.sabcs20-ps7-19
Autor:
Janice M. Walshe, Patrick Schnell, Patrick Neven, D. Lu, Reshma Mahtani, Eustratios Bananis, Lee S. Schwartzberg, Karen A. Gelmon, Meghan Sri Karuturi, Anil A. Joy, Sindy T. Kim
Publikováno v:
Cancer Research. 81:PS10-14
Background: In the PALOMA-2 trial, PAL + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in pts with ER+/HER2– ABC. This post hoc analysis assessed efficacy and safety of PAL + LET in pts from PALOMA-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::758c0bad385fc8d6a701eccc8a13c4ad
https://doi.org/10.1158/1538-7445.sabcs20-ps10-14
https://doi.org/10.1158/1538-7445.sabcs20-ps10-14
Autor:
Ethan Basch, Allison M. Deal, William A. Wood, Jordan T. Lee, Lisa A. Carey, Hyman B. Muss, Trevor A. Jolly, Shlomit S. Shachar, Addison Tucker Brenizer, E. Claire Dees, Katherine E. Reeder-Hayes, Yi Tang Chen, Raquel E. Reinbolt, Meghan Sri Karuturi, Bryce B. Reeve, Joellen C. Speca, Kirsten A. Nyrop, Gretchen Kimmick
Publikováno v:
Cancer. 127:957-967
BACKGROUND To the authors' knowledge, it is unknown whether patient-reported symptom severity and symptom interference with daily activities differ between younger (aged
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49e2a2b0753a803956e58743f3569181
https://doi.org/10.1002/cncr.33329
https://doi.org/10.1002/cncr.33329
Autor:
Yuan Liu, Meghan Sri Karuturi, Yao Wang, Joanne L. Blum, Aditya Bardia, Joseph C. Cappelleri, Debasish Tripathy, Keith L. Davis, Gabrielle B. Rocque, Zhe Zhang
Publikováno v:
Future Oncology. 16:2475-2485
This report describes the rationale, purpose and design of the POLARIS study. POLARIS is an ongoing noninterventional, prospective, multicenter study. Female and male patients in the USA and Canada diagnosed with hormone receptor-positive/HER2-negati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd721553e968d494652b8c069c09dd02
https://doi.org/10.2217/fon-2020-0573
https://doi.org/10.2217/fon-2020-0573